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ABSTRACT
Objective: To evaluate the quality of life and its association with daily physical activity and disease 
control in acromegalic patients. Subjects and methods: A cross-sectional, case series study, com-
posed of 42 patients recruited from the Neuroendocrinology Unit of the University Hospital of Brasi-
lia. Level of physical activity was accessed by the International Physical Activity Questionnaire (IPAQ 
6-short-form), which evaluates the weekly time spent on physical activity of moderate to vigorous 
intensity in different contexts of life. Quality of life was evaluated by The Medical Outcome Study Ques-
tionnaire Short Form (SF-36). Data was compared to growth hormone (GH) and insulin-like growth 
factor (IGF-1) levels. Students’ t test and Fisher test were used, p < 0.05, SPSS 17.0. Results: Twenty-
-two women, aged 51.33 ± 14.33 and 20 men, aged 46.2 ± 13.18 were evaluated. Arthralgia was present 
in 83% of cases. In men, the most common sites of pain were the knees (73%), spine (47% lumbar, and 
53% thoracic and cervical segments), hands and wrists (40%). Higher scores on SF-36 were observed 
in patients with intermediate or high levels of physical activity, in the domains social functioning (75 CI 
57.3-92.6), general health (75.5 CI 60.4-90.5), mental health (70 CI 57.8-82.1). Conclusions: In this study, 
the presence and severity of physical disability and pain were not associated with initial GH and IGF-1 
levels or time of exposure to GH excess. However, the patients considered controlled, with normal 
a normal age-adjusted IGF-1, presented higher scores in SF-36, in physical and emotional domains, 
compared with patients with persistent hypersomatotrophism. These findings suggest benefits of me-
tabolic control in self-reported quality of life. Arq Bras Endocrinol Metab. 2013;57(7):550-7
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RESUMO
Objetivo: Avaliar a qualidade de vida e sua associação com a prática de vida diária e controle metabóli-
co em pacientes portadores de acromegalia. Sujeitos e métodos: Estudo seccional de série de casos, 
composto por 42 pacientes recrutados na Unidade de Neuroendocrinologia do Hospital Universitário 
de Brasília. O nível de atividade física foi estimado pelo Questionário Internacional de Atividade Física 
(IPAQ-6), que avalia o tempo gasto semanalmente em atividades físicas que variam de intensidade em 
diferentes contextos de vida. A qualidade de vida foi avaliada pelo questionário SF-36. Os dados obtidos 
foram comparados aos níveis de hormônio do crescimento (GH) e fator de crescimento semelhante à 
insulina (IGF-1). Os testes t Students e Fisher foram aplicados e p < 0,05 foram considerados significati-
vos, SPSS 17.0. Resultados: Avaliaram-se 22 mulheres com idades de 51,33 ± 14,33 e 20 homens com 
idades de 46,2 ±13,18. Artralgia foi relatada em 83% dos pacientes. Em homens, os sítios de dor mais 
comuns foram os joelhos (73%), coluna vertebral (47% lombar, 53% segmentos torácico e cervical), 
mãos e quadris (40%). Os maiores escores no SF-36 foram observados em pacientes com níveis inter-
mediário ou alto de atividade física, sobretudo nos domínios social (75 CI 57,3-92,6), saúde geral (75,5 
CI 60,4-90,5), saúde mental (70 CI 57,8-82,1). Conclusões: A presença e a severidade do prejuízo no 
desempenho físico e dor não se associaram com Gh e IGF-1 no diagnóstico, tempo de exposição prévio 
à doença. Todavia, pacientes considerados controlados apresentaram melhores escores nos domínios 
físico e emocional, comparados com pacientes com hipersomatotrofismo persistente. Tais achados su-
gerem benefícios do controle metabólico na qualidade de vida. Arq Bras Endocrinol Metab. 2013;57(7):550-7
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INTRODUCTION
A cromegaly is a rare chronic disease, due to growth hormone (GH) and insulin-like growth factor 
(IGF-1) oversecretion (1). The estimated prevalence is 
40-70 patients for one million inhabitants, and the age 
of diagnosis occurs in most cases in the third to fifth 
decade of life. The disease is associated with reduced 
expectancy of life and high mortality related to cardio-
vascular and metabolic co-morbidities. (2,3).
The disease results in most cases from a somatotro-
pic pituitary tumor (4), but is rarely associated to neu-
roendocrine ectopic tumors and uncommon genetic 
familial syndromes (5,6). The behavior is insidious and 
the delay in diagnosis may be more than 10 years after 
the tumor development (7).
The most prevalent clinical manifestations are soft 
tissue enlargement, organomegaly, and metabolic 
complications. The cardiovascular disease is related 
to more than 60% of mortality in acromegalic pa-
tients (8). Hypertension occurs in more than 46% of 
patients with acromegaly and a higher frequency of 
classic and non-classic cardiovascular risk factors was 
described (9,10). 
The articular manifestations are frequent and may 
be present as the earliest symptom of acromegaly (11). 
Arthropathy can affect both axial and peripheral joints; 
the most involved are hips, shoulders, knees, hands, 
and elbows. It is frequently irreversible despite treat-
ment, and may contribute to decreased quality of life 
(Qol) (12). Musculoskeletal impairment is related to 
articular damage and its prevalence and severity wors-
ens with the duration of uncontrolled disease, resulting 
in significant physical disability (13). 
Some studies compared the quality of life in patients 
with several types of pituitary tumors, treated for long 
periods of time, using questionnaires to evaluate Qol, 
anxiety and depression. The authors concluded that 
patients treated for acromegaly reported more impair-
ment in physical ability and more pain compared to pa-
tients treated for nonfunctioning macroadenomas and 
prolactinomas (14). The questionnaire SF-36 has been 
described as an important tool to evaluate the self-re-
ported quality of life, and may be useful in patients with 
acromegaly (15-17).
The impairment in quality of life in acromegalic pa-
tients may be related to depression, poor self-image, 
pain, mood swings, impaired physical activity and men-
tal health (15,18). This study evaluated postural de-
fects, physical disability in daily life activities, and the 
consequences in quality of life in a cohort of Brazilian 
acromegalic patients.
AIM OF THIS STUDY
The aims of this study were to describe the impairment 
in physical ability for daily life activities and functioning, 
and compare it with the quality of life and its relation 
with the type of treatment and activity of the disease in 
acromegalic patients.
SUBJECTS AND METHODS
This is a cross-sectional, case series study that enro lled 
42 patients with confirmed diagnosis of acromegaly 
(19,20), recruited from outpatient clinics of the Neu-
roendocrine Unit of the University Hospital of Brasi-
lia. Before beginning the study, a structured anamne-
sis, medical record review, physical evaluation of each 
participant were put together to document symptoms, 
co-morbidities, current medications, and previous 
treatments. All patients were submitted to GH and 
IGF-1 determinations, using standardized chemilumi-
nescence methods (Immulite 2000-IS 98/574). The 
patients were categorized by gender, tumor size and 
invasiveness, previous treatments (surgery, radiothera-
py, medical treatment), and activity of disease (control-
led and not controlled). All patients answered specific 
questionnaires to evaluate the level of physical activity 
and quality of life. All procedures used in this study 
were in accordance with the resolution 196/96 from 
the Brazilian Ministry of Health, and were approved by 
the ethics committee from our institution. All patients 
signed an informed consent form before the inclusion 
in the study.
Evaluation of level of physical activity and  
quality of life
The level of physical activity was evaluated by the In-
ternational Physical Activity Questionnaire (IPAQ 6- 
short-form), which measures the weekly time spent 
on physical activity, from mild to vigorous intensity, in 
different contexts of life, such as work, housekeeping, 
transportation, and leisure (21).
The Qol was evaluated by The Medical Outcome 
Study Questionnaire Short Form (SF-36), which is a 
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ty of life, translated and validated for Brazil (18). This 
questionnaire is composed of 36 items, grouped in 
eight health domains: functional capacity, physical as-
pects, pain, general health, vitality, social functioning, 
emotional aspects and mental health, and self-reported 
health status (18,22).
Clinical anamnesis and evaluation of pain
Clinical anamnesis was performed and an interview 
in the form of a questionnaire was used to assess the 
patients’ perception of the presence and intensity of 
headaches and osteoarticular pain. In this instrument, 
a map demonstrating a human figure to show sites of 
discomfort by a Visual Analogue Scale for pain was pre-
sented to each patient (23). All patients were photogra-
phed in front of a white background, at a distance of 
3 meters, in anterior, posterior, right, and left position 
as proposed by Kendall (24). All patients were using 
bathing suits, and were in orthostatic position with the 
body relaxed. The data was inserted in the software 
Physical Test 6.3-Terrazul.
Statistical analysis
Student’s t test was performed for the comparative 
analysis of quantitative variables. Fisher exact test was 
used to compare frequencies and determine associa-
tions between categorical variables. The distributions 
of all continuous variables were reviewed for normality 
using the Kolmogorov-Smirnov test. Relationships be-
tween continuous variables were accessed by Spearman 
Rank or Pearson correlations. All statistical analyses 
were conducted using the Statistical Package for Social 
Sciences (SPSS 17.0) and p values < 0.05 were conside-
red statistically significant.
RESULTS
Characteristics of the sample 
The group was composed of 22 women and 20 men 
aged 53.63 ± 14.3 and 46.35 ± 13.18 years old, res-
pectively. The delay between the first symptoms and 
diagnosis for the whole cohort was 5.43 years, but no 
statistically significant differences were found between 
genders (p = 0.92). The women presented a tendency 
to have higher mean age at diagnosis than men at the 
inclusion in the study, but no statistical difference was 
found (Table 1). 
Tumor size
By the time of diagnosis, 89.4% of women had macro-
adenomas (17.05 mm; CI 95% 12.77-21.33), 36.8% 
with supra and parasellar invasion to cavernous sinus 
and carotids (Table 2). In men, 13.04% had microa-
denomas and the frequency of invasive macroadeno-
mas was 43.47% (21.35 mm; CI 95% 16.52-26.18) 
(p = 0.18 calculated by test t for difference between 
genders).
Table 1. Description of baseline characteristics of study subjects, categorized by gender
Age at diagnosis Age at the inclusion Delay symptoms and diagnosis


























p-value  0.09 0.07 0.93 0.49
p values calculated by the Student’s t test, statistically significant when < 0.05. Results are expressed in means of years, and confidence intervals (CI 95%). 
N = 42 patients.
Table 2. Distribution of frequency of tumor size and invasion at the 










Women 10.53 52.6 36.8
Men 13.04 56.5 43.47
p -value  0.09 0.93 0.18
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Frequency of symptoms reported at the diagnosis
The frequency of symptoms was categorized by gender 
(Table 3). Enlargement of soft tissue was the most pre-
valent complaint in both genders. Arthralgia was pre-
sent in 84.21% of women and 82.61% of men. Sudore-
sis and cephalea were very frequent, with no statistically 
significant differences between genders. 
Table 3. Distribution of frequency of symptoms at the diagnosis, 
categorized by gender
Symptoms Women (%) Men (%) p-value*
Enlargement of soft tissue 19 (100) 22 (95.65) 1.00
Sudoresis 17 (89.47) 22 (95.65) 0.85
Arthralgia 16 (84.21) 19 (82.61) 1.00
Cephalea 15 (78.95) 16 (69.57) 0.74
Hypogonadism 14 (73.68) 20 (86.96) 0.49
Visual Impairment 8 (42.11) 9 (39.13) 1.00
Hypertension 7 (36.84) 15 (65.22) 0.13
Acne 7 (36.84) 6 (26.09) 0.68
Galactorrhea 6 (31.58) 0 (0) *0.01
Diabetes 4 (21.05) 7 (30.43) 0.74
* p values calculated by the Fisher exact test, statistically significant when < 0.05. Results are 
expressed in percentage.
Treatment before the inclusion in the study
All patients were submitted to previous treatments, 
76.19% were submitted to one surgery, 23.6% to two 
surgeries, and 34.37% of the operated patients were 
submitted to further radiotherapy. Primary treatment 
with somatostatin analogs was prescribed to 23.80% of 
patients and 11.30% of them was treated by combined 
cabergoline and octreotide.
Metabolic control at inclusion
Considering the current criteria for cure and control 
of Acromegaly (19,20), 26.32% of women and 4.35% 
of men were considered cured, 68.42% of women and 
60.87% of men were considered controlled by medical 
treatment (p = 0.85), and the other patients were con-
sidered with uncontrolled disease, despite the previous 
and current treatments as surgery, radiotherapy, and so-
matostatin analogs (p = 0.11). 
Distribution, frequency and intensity of pain 
symptoms
More than 80% of patients complained of arthralgia by 
time of inclusion in the study. In men, the most com-
mon sites of pain were the knees (73%), spine (47%), 
hands and wrists (40%). Most of the women presen-
ted multiple sites of pain. The most frequent site was 
the spine (47% lumbar, and 53% thoracic and cervi-
cal segments). The intensity of pain was evaluated by 
a Visual Analogue Scale and was reported as intense 
by 33.3% of women and 22.2% of men, moderate by 
46.7% of women and 48.1% of men, and mild in 20% 
of women and 29.6% of men. Pain of severe intensity 
was reported more frequently on shoulders and spine. 
The frequency of pain was described as 3 to 5 days per 
week, in 53.3% of women and 7.4% of men, but 44.4% 
of men reported daily pain. There was no association 
between severity of pain and number of surgeries (r = 
0.25, p = 0.19), or time to achieve metabolic control 
(r = 0.01, p = 0.08). 
Postural defects
The analysis of the frequency of postural defects sho-
wed that 53% of men and 45% of women presented 
Genu varus, and Genu valgus was observed in 18% of 
women and 9% of men (Figure 1). Spine deviations 
(scoliosis, kyphosis or lordosis) were noted on 90% of 
patients, and 80% presented more than two deviations 
as asymmetry, scoliosis, cervical or lumbar lordosis, or 
hyperkyphosis (Figure 2). It was noted that 58% of pa-
tients had abdominal protrusions. Shoulder deviations 
were frequent, and more than two deviations (unilate-
ral or bilateral asymmetry, internal rotation) were ob-
served in 35% of men and 45% of women (Figure 3). 
There was no correlation between postural defects and 
disease activity (r = 0.6 p = 0.12), nor between postu-
ral defects and time of exposure to growth hormone 











Genu varus Genu valgus
Figure 1. Frequency of knee deviations according to gender. Gray 
columns represent women, and black columns represent men. There was 
no statistical difference between genders for Genu varus (p = 0.46), Genu 
valgus (p = 1.0) or absence of abnormalities (p = 0.44). P-value calculated 
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activity, we observed a tendency to present higher sco-
res on SF-36 (Table 4), concerning the domains social 
functioning (75 CI 57.3-92.6), general health (75.5 
CI 60.4-90.5), and mental health (70 CI 57.8-82.1), 
although no significant statistical differences were ob-
served comparing to patients with low physical activity 
level (p = 0.23, p = 0.11, p = 0.62, respectively). 
The scores obtained on SF-36 domains were com-
pared with the normal population, and were lower than 
Jenkinson and cols. data for all domains (35). In Role 
Physical and Pain, the study population obtained scores 
56.67 ± 40.44 and 55.67 ± 23.59, but previously pu-
blished data showed that in the healthy population, the 
scores were respectively 80.1 ± 34,9 and 84.8 ± 31.3 
(Table 6). Patients with intermediate or high levels of 
physical activity frequently reported pain in anamnesis, 
but presented a tendency to have higher mean score 
in the domain pain on SF-36 (65.5, 48.61 ± 82.39) 
than patients with mild level of physical activity (52.27, 
41.60 ± 62.95) (p = 0.06).
Domains of SF-36 categorized by level of disease 
activity
The patients were categorized in two groups by the 
level of activity of disease: controlled, when GH and 
IGF-1 were normal for age and gender; and uncon-
trolled, when GH or IGF-1 were higher than reference 
ranges. The scores for all domains of SF-36 presented 
a tendency to be higher in patients with controlled le-
vels of GH and IGF-1, and statistical differences were 
found in the domains Role Physical (p = 0.02), Pain (p 









None Hyper lordosis Hyperkyfosis Scoliosis 
Men Women 
Figure 2. Frequency of spine deviations according to gender. Gray 
columns represent women, and black columns represent men. There was no 
difference between groups concerning hyperlordosis (p = 1.0), hyperkyfosis 
(p = 1.0), absence of abnormalities (p = 0.67), scoliosis (p = .0.9). P-value 
















Figure 3. Frequency of shoulder deviations according to gender. There 
was no difference between genders on internal rotation (p = 0.44), right 
asymmetry (p = 0.39), right asymmetry (p = 0.43), more than 2 deviations 
right asymmetry (p = 0.70). Results are expressed in percentage. P-value 
calculated by Fisher test, p < 0.05 was considered statistically significant.
Level of physical activity and quality of life
The level of Physical Activity is expressed by weekly 
time spent on physical activity, from mild to vigorous 
intensity, in different contexts of life, and was compared 
with functional capacity score and emotional aspects. 
In patients with intermediate or high levels of physical 
Table 4. Level of Physical Activity (IPAQ-6) and Dimensions of the Analysis of Quality of Life (SF-36)
Domains
(SF-36)
Physical Activity Level (IPAQ-6)
Low Intermediate/High
Mean CI (95) Mean CI (95) p value
Physical functioning 47.95 37.65‐58.25 63.13 44.84‐81.41 0.12
Role physical 52.27 34.20‐70.34 53.13 15.34‐90.91 0.96
Pain 52.27 41.60‐62.95 65.5 48.61‐82.39 0.06
General health 62.36 52.64‐72.09 75.5 60.49‐90.51 0.11
Vitality 55.45 45.76‐65.15 59.38 46.85‐71.90 0.59
Social functioning 63.07 50.44‐75.69 75.00 57.34‐92.66 0.23
Role emotional 51.52 32.86‐70.17 58.33 25.87‐90.80 0.68
Mental health 66.73 5838‐75.07 70.00 57.88‐82.12 0.62
* p values calculated by the Student t test, statistically significant when < 0.05. Results are expressed in means and confidence intervals (CI 95%). 
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Table 6. Scores found in the domains of SF-36 in acromegalic patients 
compared with the normal population (Jenkinson and cols., 1996)
Domains (SF-36) Study cohort  n = 42
 Normal population
(Jenkinson and cols., 
1996)
n = 712
Physical functioning 67.17 ± 23.88 79.4 ± 23.88
Role physical 56.67 ± 40.44 80.1 ± 34.90
Pain 55.67 ± 23.59 84.8 ± 31.30 
General health 67.67 ± 17.03 86.9 ± 21.90
Vitality 56.50 ± 20.09 75.9 ± 17.40
Social functioning 68.13 ± 25.84 60.3 ± 20.50
Role emotional 58.73 ± 40.81 76.6 ± 25.0
Mental health 68.00 ± 17.60 68.4 ± 21.6
Results are expressed as means and standard deviations.









exposure to GH 
excess
Tumor size Time to achieve control
Number of 
surgeries
Physical functioning Correlation -0.13 -0.21 0.05 -0.42** 0.15 0.16
P-value 0.49 0.26 0.81 0.02 0.43 0.39
Role physical Correlation 0.07 -0.22 -0.08 -0.30 0.00 0.17
P-value 0.71 0.24 0.68 0.11 1.00 0.36
Pain Correlation -0.13 -0.02 0.25 -0.17 0.01 0.25
P-value 0.51 0.91 0.19 0.37 0.97 0.19
General health Correlation 0.11 0.10 0.05 -0.13 0.02 0.03
P-value 0.56 0.59 0.78 0.50 0.91 0.87
Vitality Correlation -0.02 -0.13 -0.03 -0.36 0.00 0.06
P-value 0.93 0.51 0.86 0.05 0.98 0.75
Social functioning Correlation 0.07 -0.36 -0.15 -.483 -0.22 -0.11
P-value 0.73 0.05 0.43 0.01 0.24 0.57
Role emotional Correlation 0.43* -0.16 -0.32 0.41* -0.21 -0.19
P-value 0.02 0.39 0.09 0.02 0.26 0.31
Mental health Correlation -0.07 -0.15 0.14 -0.15 0.03 0.23
P-value 0.70 0.44 0.48 0.43 0.87 0.23
Correlations calculated by Pearson test and p-values statistically significant when < 0.05.
Table 7. Analysis of domains of SF-36 in patients categorized by activity 
of the disease, as cured or active acromegaly
Domains (SF-36) Cured Mean ± SD Standard error P value
Physical functioning
Yes 71.25 ± 29.55 14.77
0.72
No 66.54 ± 23.53 4.61
Role physical
Yes 6.25 ± 12.5 6.25
0.01*
No 64.42 ± 37.53 7.36
Pain
Yes 54.75 ± 28.37 14.19
0.94
No 55.81 ± 23.42 4.59
General health
Yes 57.00 ± 14.74 7.37
0.18
No 69.31 ± 17.01 3.34
Vitality
Yes 58.75 ± 30.65 15.33
0.81
No 56.15 ± 18.83 3.69
Social functioning
Yes 68.50 ± 26.26 13.13
0.98
No 68.08 ± 26.30 5.16
Role emotional
Yes 49.75 ± 42.99 21.50
0.66
No 60.12 ± 41.17 8.07
Mental Health
Yes 66.00 ± 31.07 15.53
0.81
No 68.31 ± 15.01 2,94






























Figure 4. Dimensions of the Analysis of Quality of Life (SF-36) categorized 
in two groups, controlled and uncontrolled patients. Results are expressed 
as means and standard deviations (SD); P-value calculated by Fisher test, 
* p < 0.05 was considered statistically significant.
DISCUSSION
This is an original study evaluating the severity of im-
pairment of daily life activities and clinical aspects in 
patients with acromegaly. The data showed a high per-
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centage of postural defects in one or more regions in 
this cohort of patients. The patients reported pain in 
different muscle and joint groups and the most affected 
regions were knees and upper spine. The complaints 
about pain were daily in almost half of patients, and 
were proportional and more severe in patients with hi-
gher levels of physical activity. These results are in agre-
ement with other authors and may be related to the 
overload in joints that may worsen previous articular 
disease (16,17,25). 
The assessment of perception of the presence and 
intensity of pain was previously evaluated by a Visual 
Analogue Scale of discomfort, in other groups of sub-
jects without chronic diseases, as healthy students (29), 
and women (31) submitted to mild or intermediate 
and high levels of physical activities. The group of acro-
megalic patients in our study reported multiple sites of 
discomfort, and also greater intensity of pain than nor-
mal subjects published in other studies (24,27,31). 
The chronic exposure to GH oversecretion can be 
associated with osteoarticular damage and may lead to 
disability in daily life activities (DLA), with consequen-
ces in time spent on physical activities and quality of 
life. The patients evaluated in this study presented lo-
wer level of physical activities than age-matched control 
subjects, and data published in elderly populations. The 
problem can be worsened by the daily life activities, 
with constant changes in posture and the adoption of 
antalgic positions, postural errors and habits over time 
(32,33). 
The pathogenesis of arthropathy in acromegaly may 
involve two mechanisms: initial endocrine and subse-
quent mechanical changes (12,13). At the initial sta-
ge, GH and IGF-1 lead to hyperfunction of articular 
chondrocytes and increased matrix synthesis, resulting 
in growth of periarticular structures. Synovial hyper-
trophy further exacerbates the abnormal mechanical 
loading in the joints, which is reversible by hormone 
control. In advanced cases, the ulceration of the joint 
cartilage promotes the osteoarthritis, which cannot be 
improved by GH and IGF-1 normalization (26).
Some authors have previously described that the in-
fluence of GH and IGF-1 in the osteoarticular system 
exposes the morphofunctional structure of the indivi-
dual to possible hazards (16,17). In this study, the pre-
sence and severity of physical disability and pain were 
not correlated to initial GH and IGF-1 levels, time 
of previous exposure to GH excess, nor to metabolic 
control by the inclusion. A recent study investigated 
the clinical course of arthropathy and its relationship 
with radiographic progression in long-term controlled 
acromegaly patients, and suggested that joint func-
tion deteriorates during prolonged follow-up, despite 
biochemical control of the disease (36). It is currently 
unknown whether GH and IGF-1 control can reverse 
arthropathy in patients with acromegaly. However, im-
provement in signs and symptoms was demonstrated 
(34).
In our cohort, the patients considered controlled, 
with normal a normal age-adjusted IGF-1, presented 
higher scores in SF-36 in physical and emotional do-
mains compared with patients with persistent hyperso-
matotrophism despite previous treatments and use of 
somatostatin analogs or dopamine agonists. These fin-
dings suggest benefits of metabolic control in quality of 
life. Studies have been published seeking to demonstra-
te that the improvement or possible extinction of chro-
nic pain could improve the quality of life in different 
diseases (14,25,32). Other authors described that the 
impairment of quality of life may persist despite succes-
sful treatment in endocrine diseases (17,36). 
In conclusion, the impairment in physical ability for 
daily life activities was shown in our study, and was not 
related to the type of treatment and activity of the dise-
ase in acromegalic patients. The data suggests benefits 
of acromegaly disease control in quality of life, based on 
better scores regarding emotional and physical domains 
of SF-36. Many unanswered questions about the bene-
fits of controlled compared with uncontrolled disease 
regarding reversibility of articular co-morbidities have 
to be better evaluated in further studies. 
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